• Funding will support the platform’s launch into both clinical and commercial sectors.
• The company is focusing on the Euro 15 billion in silico trials market, along with ICU decision support.

Munich, Germany – July 2, 2025 – Ebenbuild, a company specializing in AI-powered, personalized digital lung twins for clinical decisions and digital clinical trials, has announced the receipt of Euro 2.3 million in funding from the European Innovation Council (EIC) Accelerator program. This funding aims to further develop its digital twin platform technology. Moreover, the EIC fund plans to invest up to €10 million in Ebenbuild’s future equity financing rounds. The funding will facilitate the market introduction of Twinhale, the first in silico trial software designed for pulmonary drug delivery. The investment also bolsters Ebenbuild’s broader strategy to revolutionize respiratory care via personalized lung simulation, spanning from drug development to optimizing mechanical ventilation in critical care settings.

Twinhale represents the first scalable simulation tool offering physiologically accurate, patient-specific predictions of drug distribution within the lungs. Built upon Ebenbuild’s unique technology platform, it provides pharmaceutical and medtech companies with a cost-effective means of digitally simulating pulmonary drug delivery. This has the potential to lower trial failure rates and costs, as well as shorten time-to-market.

Ebenbuild has already utilized its Twinhale software in pilot studies conducted with PARI Pharma and Pieris Pharmaceuticals. A validation study demonstrated Twinhale’s ability to predict local drug deposition with exceptional accuracy, surpassing existing models and enabling design choices that are usually unattainable through in vivo or in vitro testing.

Supported by HTGF, Bayern Kapital, and angel investors, Ebenbuild operates within the rapidly expanding Euro >5 billion in silico trials market. The company is also positioning itself to enter the clinical decision support systems (CDSS) and personalized medicine markets, which are collectively projected to exceed €300 billion by 2030. The EIC grant offers non-dilutive capital and validation from one of Europe’s most selective tech funding programs.

“Our vision is to establish ourselves as the premier health intelligence platform for respiratory diseases,” stated Dr. Kei Müller, CEO and  Co-founder of the Company. “Twinhale is merely the initial step. The same core platform will drive future regulated products for optimizing mechanical ventilation and managing chronic respiratory diseases.”

Dr. Maximilian Grill, Head of In Silico Trials at Ebenbuild, commented: “Twinhale allows us to not only lower attrition rates in respiratory drug development but also generate novel datasets that can promote regulatory acceptance and unlock companion diagnostic strategies in the future.”

The Company’s long-term plan encompasses preclinical simulations and clinical-grade decision support systems. As a subsequent product, Ebenbuild is developing software to optimize mechanical ventilation for patients with lung complications – a Euro 10 billion market segment characterized by strong clinical demand, rapid feedback loops, and clear economic advantages.

###

About Ebenbuild
Ebenbuild is an innovative digital health technology company developing precise computer models of lungs, known as digital twins, using patient-specific data. Their digital toolset incorporates physics-based simulation, A.I., and data science to assist decision-makers in the life sciences and healthcare sectors. Ebenbuild’s platform technology enhances the understanding of respiratory diseases and individual pathophysiology, facilitating products ranging from personalized decision support for improved patient outcomes in severe respiratory diseases to in silico trials that accelerate and de-risk inhaled drug development.

About EIC Accelerator
The EIC Accelerator provides start-ups and SMEs with grants of up to €2.5 million, along with equity investments ranging from €0.5 to €15 million (up to €10 million as of 2025) through the EIC Fund. In addition to financial support, all projects benefit from Business Acceleration Services, offering access to leading expertise, corporate partners, investors, and key players in the ecosystem.

Company Contact
Ebenbuild
Dr. Jonas Biehler

Media Inquiries
akampion
Dr. Ludger Wess / Ines-Regina Buth
Managing Partners
info@akampion.com
Tel. +49 40 88 16 59 64 / +49 30 23 63 27 68

“`